NCT07090161View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions
HypertensionUncontrolled Hypertension
Interventions
DRUG

iloperidone

iloperidone

DRUG

Placebo

placebo comparator

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY